Abciximab (ReoPro) is the Fab fragment of a human-murine chimeric monoclonal antibody originally directed against the human platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. Abciximab acts as a potent, non-competitive antagonist by binding to the GPIIb/IIIa receptor on the surface of platelets, thereby preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. This blockade is the final common pathway for platelet aggregation. It is primarily used as an adjunct to percutaneous coronary intervention (PCI) for the prevention of ischemic cardiac complications. Due to its mechanism and relatively long half-life, its clinical use has been associated with a risk of bleeding and thrombocytopenia.